MASLD essentials
- Metabolic dysfunction-associated steatotic liver disease, or MASLD, is one category within the broader steatotic liver disease framework.
- MASLD can be silent, and one liver enzyme, ultrasound, body-size measure, or online fibrosis score cannot diagnose its cause or stage.
- Clinicians assess metabolic context, alcohol exposure, other liver causes, laboratory information, imaging, and fibrosis risk together.
- Current medicines for MASH have narrow adult, noncirrhotic, clinician-confirmed indications; they are not treatments for everyone with liver fat.
- Vomiting blood, black or tarry stool, severe confusion, fever with shaking, or sudden jaundice in a person with advanced liver disease requires emergency evaluation.
What MASLD and MASH mean
Steatotic liver disease, or SLD, is an umbrella term for conditions involving excess fat in the liver. Metabolic dysfunction-associated steatotic liver disease, or MASLD, describes a specific combination of liver fat and cardiometabolic context after clinicians consider other causes. Metabolic dysfunction-associated steatohepatitis, or MASH, includes inflammation and liver-cell injury within that framework.
Other SLD categories include disease related to substantial alcohol exposure, a combined metabolic and alcohol category known as MetALD, specific causes such as certain medicines or genetic conditions, and cryptogenic disease when a cause remains unclear. These categories should not be collapsed. A person’s alcohol history deserves a private, nonjudgmental discussion because it affects classification and safety.
Older records and websites may use nonalcoholic fatty liver disease, or NAFLD, and nonalcoholic steatohepatitis, or NASH. Those terms can help people recognize earlier diagnoses, but they should not be used to relabel someone without clinical review. The updated terminology is meant to describe disease more accurately, not to assign blame.
Why MASLD can be silent
Many people do not notice liver-specific symptoms. The condition may first be considered after abnormal liver tests, an imaging report that mentions steatosis, or an evaluation for diabetes, cholesterol, blood pressure, or another health issue. A lack of symptoms does not exclude inflammation or fibrosis, and symptoms cannot determine the stage.
Fatigue or discomfort on the right side of the abdomen may occur, but these are nonspecific and have many possible causes. Routine liver enzymes may be normal even when important disease is present, or elevated for reasons unrelated to MASLD. One laboratory result cannot show whether there is fibrosis or explain why the liver is affected.
Finding liver fat on ultrasound or another scan also does not settle the diagnosis. Imaging methods differ in what they can detect, and they do not all measure inflammation or scarring. The report must be interpreted with the history, laboratory information, metabolic health, medicine and supplement use, and evaluation for other liver diseases.
Metabolic and other context without blame
MASLD is associated with cardiometabolic factors such as type 2 diabetes, abnormal blood lipids, high blood pressure, and body composition. Sleep disorders, medicines, genetics, age, menopause, disability, food and activity environments, stress, income, and access to care can also shape risk and the ability to manage health.
No single food, behavior, or body-size category explains an individual case. People in smaller bodies can have MASLD, and not everyone in a larger body has it. Respectful care should focus on health needs and practical support rather than shame, assumptions about eating or alcohol, or the idea that disease reflects willpower.
Other explanations for steatosis or liver injury must still be considered. Viral hepatitis, autoimmune or inherited conditions, medication-related injury, and alcohol-related disease may overlap with metabolic risk. That is why an online checklist or old “fatty liver” label is not enough to choose a category.
How clinicians evaluate possible disease
Evaluation can include medical and family history, alcohol and medicine review, examination, and laboratory testing. Clinicians look for cardiometabolic conditions and for evidence of another liver cause. They may review previous results over time because a single value provides limited information.
Noninvasive approaches may combine routine clinical data, blood-based scores, or liver stiffness assessment to estimate the chance of advanced fibrosis. These tools are designed for particular populations and settings. Age, acute illness, laboratory variation, and other conditions can affect results. Entering numbers into an online fibrosis calculator cannot diagnose or stage MASLD on its own.
Imaging and, for selected people, liver biopsy can answer additional questions, but neither is automatically required for everyone. The choice depends on the uncertainty, estimated fibrosis risk, other possible diagnoses, and whether the result would change care. A clinician should explain what each test is intended to establish.
Liver fat, inflammation, and fibrosis are different
Steatosis refers to fat in the liver. MASH adds inflammatory injury. Fibrosis means scar tissue, and cirrhosis is advanced structural scarring. These concepts are related but are not interchangeable. A scan showing fat does not reveal all of them, and the amount of discomfort does not indicate fibrosis stage.
Fibrosis assessment matters because it helps guide monitoring and referral. The process may begin in primary care and involve a liver specialist when results suggest greater risk, are unclear, or conflict. A borderline or unexpected score should prompt interpretation, not panic or a self-selected treatment.
Disease course differs between people. This page does not predict progression, regression, cirrhosis, or treatment response. Avoid claims that a detox, supplement, medication, food plan, or particular amount of weight change will “reverse” the liver for everyone.
Broad management and follow-up
Care can include management of diabetes, blood pressure, blood lipids, sleep disorders, and other cardiometabolic conditions; individualized nutrition and movement support; review of alcohol, medicines, and supplements; vaccination and preventive care where appropriate; and follow-up based on liver risk. The combination should fit the person’s health, culture, disability, resources, and goals.
A public guide cannot prescribe a calorie target, weight-loss percentage, diet pattern, exercise program, or alcohol limit. Those decisions depend on nutritional status, eating-disorder history, mobility, medicines, pregnancy, other conditions, and the actual liver diagnosis. Supplements and “liver detoxes” can cause harm or interact with treatment and should be disclosed to the care team.
Follow-up may use laboratory tests, repeat risk assessment, imaging, or specialist review. The schedule is not universal. Ask which result is being monitored, what change would alter the plan, and who is responsible for reviewing it. Cardiovascular health is part of care, not a distraction from the liver.
Current MASH medicines have narrow indications
U.S. approvals now include medicines for selected adults with clinician-confirmed, noncirrhotic MASH and moderate-to-advanced fibrosis consistent with stages F2–F3. These accelerated approvals do not make the medicines general treatments for all MASLD, incidental liver fat, or elevated liver enzymes. The older statement that no medicine is approved is no longer current for these narrow populations.
Resmetirom and semaglutide have different prescribing information, evidence, risks, contraindications, interactions, and monitoring needs. Eligibility requires clinical confirmation and cannot be inferred from an ultrasound, an online score, body size, diabetes, or an old NASH label. This page does not compare the medicines or predict benefit.
The approval context described here does not extend to cirrhosis, children, pregnancy, or another liver disease. Accelerated approval also means continuing evidence and regulatory updates matter. A liver specialist or appropriate treating clinician must determine whether any medicine is relevant and how it fits broader care.
Advanced liver disease and emergency signs
Most people being evaluated for uncomplicated MASLD do not present with the emergency signs of decompensated cirrhosis. The following warning is for people with cirrhosis or suspected advanced liver disease and should not be read as a list of routine MASLD symptoms.
Vomiting blood, black or tarry stools, severe confusion or unusual sleepiness, fever with shaking, or sudden jaundice requires emergency evaluation. Do not drive if severely ill or confused, and do not wait for a liver test or online score. Increasing abdominal swelling, significant leg swelling, persistent vomiting, new jaundice, or rapidly worsening weakness also needs prompt assessment; altered consciousness or severe illness makes it an emergency.
New concerning symptoms can have causes other than MASLD. Emergency clinicians need the medicine list, relevant diagnoses, recent procedures, and any known cirrhosis history. Do not use supplements, alcohol, fasting, or medicine changes as an attempt to manage a possible complication at home.
Questions for a care visit
Ask which SLD category the clinician is considering, what evidence shows liver fat, and which other causes have been assessed. Clarify whether there is evidence of MASH or fibrosis and what each test can and cannot determine. An older NAFLD or NASH label may need review rather than automatic replacement.
Ask how diabetes, blood pressure, lipids, sleep, medicines, supplements, and alcohol context affect the plan. Discuss nutrition and movement support that is realistic and non-stigmatizing. Name cost, transport, food access, language, disability, mental health, or caregiving barriers so care can be adapted.
If a medicine is mentioned, ask which confirmed indication it addresses, how cirrhosis was excluded, what monitoring is required, what uncertainties remain, and whether approval is accelerated. Ask when specialist referral or repeat fibrosis assessment is appropriate and which symptoms should trigger urgent or emergency help.
Official sources
- AASLD: Clinical Assessment and Management of MASLD
- AASLD: New MASLD Nomenclature
- EASL-EASD-EASO: 2024 MASLD Clinical Practice Guidelines
- FDA: Drug Trials Snapshot: Rezdiffra
- FDA: Approval of Semaglutide for MASH
- NIDDK: NAFLD and NASH Background
- NIDDK: NAFLD and NASH Diagnosis
- U.S. Department of Veterans Affairs: When to Go to the Emergency Room for Cirrhosis